Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

It still takes years to debar a physician convicted of a crime from conducting clinical research.

You may also be interested in...

FDA’s Rulemaking To-Do List Includes Clarifying Citizen Petitions And Orphan Drug Designations

FDA pending actions include proposed rules on the handling of citizen petitions, eligibility for orphan drug designation and post-market safety reporting for combination products.

FDA Will Revise Investigator Disqualification Regs In Response To GAO Report

The agency will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories.

FDA Will Move Faster To Ban Bad Actors From Clinical Trials

Recent changes will speed FDA's process for barring non-compliant clinical trial investigators from future product research, agency staffers say

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts